Live Breaking News & Updates on William Lumry

Stay updated with breaking news from William lumry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –

. ....

United States , Maeve Oconnor , William Lumry , Markus Heckmann , Matthew Iverson , Cristine Radojicic , Sally Van Kooten , Jonathan Bernstein , James Hao , Sandra Christiansen , Andrea Zanichelli , Constance Katelaris , Henriette Farkas , Marcus Maurer , Douglash Jones , Ricardo Zwiener , Hilary Longhurst , Paulk Audhya , Emel Ayg , Sherry Danese , Julie Ulloa , Michael Smith , Danielf Soteres , Bob Geng , Shawn Czado , James Wedner ,

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allerg

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) $KALV KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro. ....

United Kingdom , United States , Mashonaland East , Paul Audhya , Maeve Oconnor , Neil Malloy , Anetes Grumach , Douglash Jones , Timothy Craig , Ricardo Zwiener , Michael Manning , Shawn Czado , Markus Heckmann , Cristine Radojicic , Sherry Danese , Paula Busse , James Wedner , Bryan Baker , Andrea Zanichelli , Michael Smith , Julie Ulloa , Marc Riedl , Matthew Iverson , William Lumry , Vibha Desai , Bob Geng ,

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster. ....

United States , Instagram Astriatx , Chris Morabito , William Lumry , Astria Therapeutics Inc , Drug Administration , American College Of Allergy , Exchange Commission , Astria Therapeutics , American College , Chief Medical Officer , Hereditary Angioedema , Clinical Professor , Internal Medicine , Texas Health Science Center , Looking Statements , Annual Report ,

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Heredit

BOSTON (BUSINESS WIRE) Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) in Anaheim,. ....

United States , Chris Morabito , William Lumry , Instagram Astriatx , Exchange Commission , Astria Therapeutics Inc , American College Of Allergy , Drug Administration , Astria Therapeutics , American College , Chief Medical Officer , Hereditary Angioedema , Clinical Professor , Internal Medicine , Texas Health Science Center , Looking Statements , Annual Report ,

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in. ....

United States , Instagram Astriatx , William Lumry , American College Of Allergy , Exchange Commission , Drug Administration , Astria Therapeutics Inc , Astria Therapeutics , American College , Annual Scientific Meeting , Clinical Professor , Internal Medicine , Texas Health Science Center , Hereditary Angioedema , Poster Section , Exhibit Hall , Looking Statements , Annual Report ,